Takeda Pharmaceutical Company Limited
COMBINATION THERAPIES USING CD-38 ANTIBODIES
Last updated:
Abstract:
Methods of administering isolated anti-CD38 antibodies in combination with lenalidomide or pomobdomide, and dexamethasone and, optionally, bortezomib, for the treatment of multiple myeloma.
Status:
Application
Type:
Utility
Filling date:
9 Jun 2020
Issue date:
4 Aug 2022